|Bid||38.39 x 1400|
|Ask||38.56 x 3200|
|Day's Range||38.21 - 38.66|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||38.78|
|Earnings Date||Feb. 01, 2017 - Feb. 06, 2017|
|Forward Dividend & Yield||2.03 (5.27%)|
|Ex-Dividend Date||Nov. 12, 2020|
|1y Target Est||48.50|
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Glassdoor’s Employees’ Choice Awards features a list of business across a range of sectors, including finance, manufacturing, pharmaceuticals, insurance, technology and food.
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).